| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
Laminin receptor; Laminin 925-933 targets the laminin receptor, binding to it at a concentration of 1 mg/mL. This peptide corresponds to the functional active site on the laminin B1 chain involved in cell attachment, chemotaxis, and laminin receptor binding. It exhibits different modulatory effects on laminin-induced cellular activities across cell types: acting as a laminin agonist in human SK HEP-1 cells and as a partial antagonist in embryonic chick endothelial cells.
|
|---|---|
| ln Vitro |
Laminin, murine epidermal growth factor (mEGF), and the synthetic laminin peptide Lam.B1(925-933) (a linear peptide from the B1 chain of murine laminin, CDPGY1GSR-amide) all stimulate endothelial cell motility above basal rates, whereas a synthetic mEGF fragment, mEGF33-42 (a linear peptide from the C-loop of mEGF, acetyl-C-[S-Acm]-VIGYSGDR-C-[S-Acm]-amide), inhibits motility. In both human SK HEP-1 and embryonic chick endothelial cells, mEGF33-42 blocks both EGF- and laminin-stimulated locomotion of endothelial cells [1].
In in vitro cell studies, Laminin 925-933 at concentrations of 100 and 300 μg/mL stimulates the attachment of HT-1080 human fibrosarcoma cells and CHO Chinese hamster ovary cells to culture plates. In B16/F10 murine melanoma cells, this peptide induces chemotaxis while inhibiting chemotaxis induced by full-length laminin, but does not affect fibronectin-induced chemotaxis. When conjugated to an agarose hydrogel backbone, Laminin 925-933 enhances neurite outgrowth in isolated chick embryo dorsal root ganglia and PC12 cells. A 78% reduction in cell attachment was observed on films containing this peptide in the cell plating medium. |
| ln Vivo |
In vivo, mEGF33-42 also blocks both laminin- and mEGF-induced angiogenesis in the chick. In the human cell line. Lam.B1(925-933) has an additive effect in coincubation with either laminin or mEGF, but it blocks their effects in the chick cells. Lam.B1(925-933) alone stimulates angiogenesis in the chick but blocks laminin-induced angiogenesis. Thus, mEGF33-42 acts as a general laminin antagonist, whereas Lam.B1(925-933) acts as a laminin agonist in human cells, but in chick cells it acts as a partial antagonist. We propose that the presence of an anionic group at the eighth residue of mEGF33-42 may be the source of the antagonistic effects seen with this peptide as compared with the laminin fragment. These findings have important implications in the design of human antiangiogenic agents, and also in the use of chick models in the study of human disease [1].
In in vivo chick embryo studies, Laminin 925-933 alone stimulates angiogenesis but blocks laminin-induced angiogenesis. In in vivo animal studies, Laminin 925-933-derivatized gels enhance nerve regeneration in a transected rat dorsal root model compared to underivatized gels. The YIGSR active sequence within this nonapeptide has been shown to inhibit both angiogenesis and solid tumor growth. |
| Cell Assay |
Cell Adhesion Assay: HT-1080 or CHO cells are seeded onto culture plates containing Laminin 925-933 peptide at concentrations of 100 or 300 μg/mL. After incubation under appropriate conditions, non-adherent cells are removed by washing, and adherent cells are counted or stained for evaluation. Chemotaxis Assay: In Boyden chambers, B16/F10 murine melanoma cells are incubated with Laminin 925-933, and cell migration through filter membranes is quantified to evaluate the peptide's effect on chemotaxis. Neurite Outgrowth Assay: Laminin 925-933 conjugated to an agarose hydrogel backbone is used as a three-dimensional substrate. Chick embryo dorsal root ganglia or PC12 cells are seeded into this matrix, and neurite length is measured by microscopy.
|
| Animal Protocol |
Chick Angiogenesis Assay: In the chick chorioallantoic membrane model, Laminin 925-933 is applied alone or in combination with laminin. Angiogenesis is assessed by counting vascular branch points or measuring vessel density. Rat Nerve Regeneration Assay: In a transected rat dorsal root model, Laminin 925-933-derivatized hydrogels are implanted. Nerve regeneration is evaluated by histology and functional assessment, comparing with underivatized gels, laminin gels, and saline-filled nerve guidance channels.
|
| References | |
| Additional Infomation |
Laminin 925-933 (CAS: 110590-60-8) is the active peptide fragment of the laminin B1 chain, in which YIGSR is the core active sequence. The TFA salt form of this peptide has the CAS number 2828432-44-4 and a molecular weight of 1081.08. The YIGSR sequence has been shown to promote the adhesion of various epithelial cells and possesses the potential to inhibit angiogenesis and solid tumor growth.
|
| Molecular Formula |
C40H62N12O14S
|
|---|---|
| Molecular Weight |
967.05728
|
| Exact Mass |
966.423
|
| Elemental Analysis |
C, 49.68; H, 6.46; N, 17.38; O, 23.16; S, 3.32
|
| CAS # |
110590-60-8
|
| Related CAS # |
Laminin (925-933)(TFA);2828432-44-4
|
| PubChem CID |
9811758
|
| Sequence |
H-Cys-Asp-Pro-Gly-Tyr-Ile-Gly-Ser-Arg-OH; Cys-Asp-Pro-Gly-Tyr-Ile-Gly-Ser-Arg;
L-cysteinyl-L-alpha-aspartyl-L-prolyl-glycyl-L-tyrosyl-L-isoleucyl-glycyl-L-seryl-L-arginine
|
| SequenceShortening |
CDPGYIGSR
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
-6.2
|
| Hydrogen Bond Donor Count |
15
|
| Hydrogen Bond Acceptor Count |
17
|
| Rotatable Bond Count |
28
|
| Heavy Atom Count |
67
|
| Complexity |
1780
|
| Defined Atom Stereocenter Count |
8
|
| SMILES |
CC[C@@H]([C@H](NC([C@@H](NC(CNC([C@@H]1CCCN1C([C@@H](NC([C@@H](N)CS)=O)CC(O)=O)=O)=O)=O)CC2=CC=C(O)C=C2)=O)C(NCC(N[C@H](C(N[C@H](C(O)=O)CCCNC(N)=N)=O)CO)=O)=O)C
|
| InChi Key |
NGBBIWFVAWMQKZ-JDIVNGTKSA-N
|
| InChi Code |
InChI=1S/C40H62N12O14S/c1-3-20(2)32(37(63)46-17-30(56)48-27(18-53)35(61)49-24(39(65)66)6-4-12-44-40(42)43)51-34(60)25(14-21-8-10-22(54)11-9-21)47-29(55)16-45-36(62)28-7-5-13-52(28)38(64)26(15-31(57)58)50-33(59)23(41)19-67/h8-11,20,23-28,32,53-54,67H,3-7,12-19,41H2,1-2H3,(H,45,62)(H,46,63)(H,47,55)(H,48,56)(H,49,61)(H,50,59)(H,51,60)(H,57,58)(H,65,66)(H4,42,43,44)/t20-,23-,24-,25-,26-,27-,28-,32-/m0/s1
|
| Chemical Name |
(2S)-2-[[(2S)-2-[[2-[[(2S,3S)-2-[[(2S)-2-[[2-[[(2S)-1-[(2S)-2-[[(2R)-2-amino-3-sulfanylpropanoyl]amino]-3-carboxypropanoyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid
|
| Synonyms |
Laminin (925-933); 110590-60-8; Cys-Asp-Pro-Gly-Tyr-Ile-Gly-Ser-Arg; (2S)-2-[[(2S)-2-[[2-[[(2S,3S)-2-[[(2S)-2-[[2-[[(2S)-1-[(2S)-2-[[(2R)-2-amino-3-sulfanylpropanoyl]amino]-3-carboxypropanoyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.0341 mL | 5.1703 mL | 10.3406 mL | |
| 5 mM | 0.2068 mL | 1.0341 mL | 2.0681 mL | |
| 10 mM | 0.1034 mL | 0.5170 mL | 1.0341 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
